{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:08:39Z","timestamp":1740107319111,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00415-024-12245-z","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:02:27Z","timestamp":1708668147000},"page":"2902-2905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report"],"prefix":"10.1007","volume":"271","author":[{"given":"Kana","family":"Ohnari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-5592","authenticated-orcid":false,"given":"Tomoyo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Iwanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ohnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"12245_CR1","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O\u2019Brien FL, Booth HDE, Howard Jr JF, REGAIN Study Group","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O\u2019Brien FL, Booth HDE, Howard Jr JF, REGAIN Study Group (2021) Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology 96:e610\u2013e618. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","journal-title":"Neurology"},{"key":"12245_CR2","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.253973","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M (2017) Early fast-acting treatment strategy generalized myasthenia gravis. Muscle Nerve 55:794\u2013801. https:\/\/doi.org\/10.1002\/mus.253973","journal-title":"Muscle Nerve"},{"key":"12245_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard","year":"2018","unstructured":"Howard JF (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113\u2013128. https:\/\/doi.org\/10.1111\/nyas.13522","journal-title":"Ann N Y Acad Sci"},{"key":"12245_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis Mar. Drugs 78:367\u2013376. https:\/\/doi.org\/10.1007\/s40265-018-0875-9","journal-title":"Drugs"},{"key":"12245_CR5","doi-asserted-by":"publisher","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R, REGAIN study group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013987. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"12245_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105630","volume":"189","author":"M Yanagidaira","year":"2020","unstructured":"Yanagidaira M, Nishida Y, Yokota T (2020) Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy. Clin Neurol Neurosurg 189:105630. https:\/\/doi.org\/10.1016\/j.clineuro.2019.105630","journal-title":"Clin Neurol Neurosurg"},{"key":"12245_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/acn3.51376","volume":"8","author":"Howard JF, Karam C, Yountz M, O\u2019Brien FL, Mozaffar T for the REGAIN Study Group","year":"2021","unstructured":"Howard JF, Karam C, Yountz M, O\u2019Brien FL, Mozaffar T for the REGAIN Study Group (2021) Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol 8:1398\u20131407. https:\/\/doi.org\/10.1002\/acn3.51376","journal-title":"Ann Clin Transl Neurol"},{"key":"12245_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 64:212\u2013215. https:\/\/doi.org\/10.1002\/mus.27326","journal-title":"Muscle Nerve"},{"key":"12245_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.286.5439.503","volume":"286","author":"M Akaaboune","year":"1999","unstructured":"Akaaboune M, Culican SM, Turney SG, Lichtman JW (1999) Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo. Science 286:503\u2013507. https:\/\/doi.org\/10.1126\/science.286.5439.503","journal-title":"Science"},{"key":"12245_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ydbio.2005.09.041","volume":"288","author":"EG Bruneau","year":"2005","unstructured":"Bruneau EG, Macpherson PC, Goldman D, Hume RI, Akaaboune M (2005) The effect of agrin and laminin on acetylcholine receptor dynamics in vitro. Dev Biol 288:248\u2013258. https:\/\/doi.org\/10.1016\/j.ydbio.2005.09.041","journal-title":"Dev Biol"},{"key":"12245_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, Obaid AH, Oxendine SR, Oh S, Payne AS, Nowak RJ, O\u2019Connor KC (2023) Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol 146:319\u2013336. https:\/\/doi.org\/10.1007\/s00401-023-02603-y","journal-title":"Acta Neuropathol"},{"key":"12245_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","volume":"3","author":"M Maurer","year":"2015","unstructured":"Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V, Clairac G, Tzartos S, Fadel E, Eymard B, Fuchs S, Souroujon MC, Berrih-Aknin S (2015) IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun 3:1. https:\/\/doi.org\/10.1186\/s40478-014-0179-6","journal-title":"Acta Neuropathol Commun"},{"key":"12245_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","volume":"37","author":"E T\u00fcz\u00fcn","year":"2011","unstructured":"T\u00fcz\u00fcn E, Huda R, Christadoss P (2011) Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun 37:136\u2013143. https:\/\/doi.org\/10.1016\/j.jaut.2011.05.006","journal-title":"J Autoimmun"},{"key":"12245_CR14","doi-asserted-by":"publisher","first-page":"39716","DOI":"10.1038\/srep39716","volume":"7","author":"CJ Molin","year":"2017","unstructured":"Molin CJ, Westerberg E, Punga AR (2017) Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. Sci Rep 7:39716. https:\/\/doi.org\/10.1038\/srep39716","journal-title":"Sci Rep"},{"key":"12245_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3389\/fneur.2019.01343","volume":"10","author":"JT Vilquin","year":"2019","unstructured":"Vilquin JT, Bayer AC, Le Panse R, Berrih-Aknin S (2019) The muscle is not a passive target in myasthenia gravis. Front Neurol 10:1343. https:\/\/doi.org\/10.3389\/fneur.2019.01343","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12245-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12245-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12245-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T07:16:53Z","timestamp":1714202213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12245-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12245"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12245-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki. We reviewed our institution\u2019s criteria and confirmed that ethics approval was not required as long as the report was a case report, and informed consent was obtained from the patient. We confirm that we have read the journal\u2019s position on ethical publication issues and confirm that this work complies with these guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient has consented to the submission of the case report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}